MARKET

CYAD

CYAD

Celyad Oncology
NASDAQ
1.010
+0.020
+2.05%
Closed 16:00 12/02 EST
OPEN
0.9997
PREV CLOSE
0.9897
HIGH
1.040
LOW
0.9877
VOLUME
4.64K
TURNOVER
2.93K
52 WEEK HIGH
5.32
52 WEEK LOW
0.9451
MARKET CAP
22.82M
P/E (TTM)
-0.7414
1D
5D
1M
3M
1Y
5Y
Celyad Oncology reports Q3 results
Seekingalpha · 11/10 08:24
Celyad Oncology Reports Q3 Financial Review As Of September 30, The Company Had Cash And Cash Equivalents Of $13.1M; Clinical Updates Expected By End Of Year For The Phase 1 Dose-escalation IMMUNICY-1 Trial For Lead ShRNA-based Allogeneic Car T Candidate
Benzinga · 11/10 06:52
Celyad touches 52-week low after William Blair downgrades rating as company scraps colorectal cancer therapy trial
Seekingalpha · 10/13 15:29
Celyad Oncology Provides Strategic Update
MONT-SAINT-GUIBERT, Belgium, October 12, 2022--Regulatory News: Celyad Oncology (Euronext & Nasdaq: CYAD), a biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today provided an ...
Business Wire · 10/12 05:00
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Benzinga · 09/20 12:15
Celyad to sell cell therapy manufacturing site to Cellistic for €6M
Ncardia's unit Cellistic is acquiring ...
Seekingalpha · 09/20 10:17
BRIEF-Cellistic To Acquire Celyad Oncology's Manufacturing Business Unit For EUR 6 Mln
BRIEF-Cellistic To Acquire Celyad Oncology's Manufacturing Business Unit For EUR 6 Mln
Reuters · 09/20 05:12
BLUE, INVZ and AQST are among pre market gainers
Euro Tech Holdings Company (CLWT) +39%. SilverSun Te...
Seekingalpha · 08/10 12:40
More
About CYAD
Celyad Oncology SA, formerly Celyad SA is a Belgium-based company. The Company is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The Company's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). It also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).

Webull offers kinds of Celyad Oncology SA stock information, including NASDAQ:CYAD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYAD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CYAD stock methods without spending real money on the virtual paper trading platform.